Chromosomal imbalances detected via RNA-sequencing in 28 cancers.
Ozcan Z, Lucas FAS, Wong JW, Chang K, Stopsack KH, Fowler J, Jakubek YA, Scheet P.
Bioinformatics. 2022 Jan 06. PMID: 34999743
Overview
I am a molecular and clinical epidemiologist with a focus on cancer epidemiology and a background as a board-certified internal medicine physician. My main research interest is how potentially modifiable exposures cause solid tumors through genomic heterogeneity and influence cancer progression. I am passionate about combining well-defined observational studies and state-of-the-art genomics in order to guide cancer prevention and treatment. My methodologic and teaching interests include application and further development of epidemiologic methods for high-dimensional biomarker studies and clinical studies.
MD, Dr. med., 2013, Medicine
University of Freiburg, Freiburg, Germany
MPH, 2014, Biostatistics and Epidemiology
Harvard School of Public Health, Boston, MA
Residency, Board certification, 2017, Internal Medicine
Mayo Clinic, Rochester, MN
Postdoctoral training, 2021, Cancer Epidemiology
Memorial Sloan Kettering Cancer Center, New York, NY
Bibliography
p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up.
Stopsack KH, Salles DC, Vaselkiv JB, Grob ST, Mucci LA, Lotan TL.
Eur Urol Oncol. 2021 Dec 27. PMID: 34969655
Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays.
Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vaselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA.
Elife. 2021 Dec 23. 10. PMID: 34939926
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors.
Stopsack KH, Nandakumar S, Arora K, Nguyen B, Vasselman SE, Nweji B, McBride SM, Morris MJ, Rathkopf DE, Slovin SF, Danila DC, Autio KA, Scher HI, Mucci LA, Solit DB, Gönen M, Chen Y, Berger MF, Schultz N, Abida W, Kantoff PW.
Clin Cancer Res. 2021 Oct 19. PMID: 34667026
Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research.
Hurwitz LM, Agalliu I, Albanes D, Barry KH, Berndt SI, Cai Q, Chen C, Cheng I, Genkinger JM, Giles GG, Huang J, Joshu CE, Key TJ, Knutsen S, Koutros S, Langseth H, Li SX, MacInnis RJ, Markt SC, Penney KL, Perez-Cornago A, Rohan TE, Smith-Warner SA, Stampfer MJ, Stopsack KH, Tangen CM, Travis RC, Weinstein SJ, Lang PhD W, Jacobs EJ, Mucci LA, Platz EA, Cook MB.
J Natl Cancer Inst. 2021 Jun 01. 113(6):727-734. PMID: 33010161
Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer.
Drago JZ, Gönen M, Thanarajasingam G, Sacks CA, Morris MJ, Kantoff PW, Stopsack KH.
J Natl Cancer Inst. 2021 May 04. 113(5):553-561. PMID: 32857839
In search of the optimal setting for statin trials in prostate cancer: the power of population-based studies.
Allott EH, Craig EL, Stopsack KH.
Prostate Cancer Prostatic Dis. 2021 09. 24(3):583-584. PMID: 33782544
Statins and Prostate Cancer: Bias, Precision Medicine, or Population Health?
Stopsack KH.
Eur Urol. 2021 04. 79(4):453-455. PMID: 33551298
Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells.
Pan W, Zhang Z, Kimball H, Qu F, Berlind K, Stopsack KH, Lee GM, Choueiri TK, Kantoff PW.
Clin Cancer Res. 2021 04 01. 27(7):2087-2099. PMID: 33495313